Welcome to our dedicated page for Radius Recycling news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Recycling stock.
Radius Recycling, Inc. (NASDAQ: RDUS), formerly known as Schnitzer Steel Industries, Inc., stands as a prominent figure in North America's recycling and steel manufacturing industry. Established in 1906 in Portland, Oregon, the company has evolved from a small, one-man scrap metal operation into a major player in the market, boasting a diversified and vertically integrated business model.
Radius Recycling specializes in the recycling of ferrous and nonferrous metals, including end-of-life vehicles, and the manufacture of finished steel products. Their operational network comprises 54 metals recycling facilities, 50 self-service auto parts stores, and an electric arc furnace steel mill. This extensive infrastructure enables Radius to meet global demand efficiently.
Key Business Units:
- Metals Recycling Business: Processes a substantial quantity of recycled ferrous and nonferrous metals, significantly contributing to environmental sustainability and resource conservation.
- Auto Parts Business: Operates 50 retail stores selling serviceable parts from salvaged vehicles, receiving over 4 million annual visits from retail customers.
- Steel Manufacturing Business: Produces a variety of finished steel products, including rebar and wire rod, using eco-friendly electric arc furnace technology.
Despite the challenges posed by tight supply flows and adverse weather conditions impacting sales volumes, Radius Recycling has demonstrated resilience and adaptability. Recent productivity initiatives aim to reduce selling, general, and administrative expenses by 10%, alongside increasing production efficiencies, expected to yield $40 million in annual benefits.
Recent Financial Highlights:
- Revenue: Achieved $2.5 billion in fiscal 2014, reflecting robust market presence and operational efficiency.
- Global Reach: Positions in 25 states, Puerto Rico, and Western Canada, with deep-water export facilities expanding its market access.
- Strategic Initiatives: Focused on enhancing nonferrous production and expanding recycling services, positioning the company favorably against market headwinds.
Under the leadership of Tamara Lundgren, Chairman and CEO, Radius Recycling remains focused on cost control, operational efficiency, and strategic growth. The company's commitment to sustainability and low-carbon technologies aligns with global decarbonization trends, positioning Radius to capitalize on future market opportunities.
Partnerships and Projects: Radius continues to invest in advanced metal recovery technologies and expand its recycling platform, supporting its mission of promoting environmental sustainability and efficient resource use.
The company will report its financial results for the second quarter of fiscal 2024 on April 4, 2024, with a webcast conference call hosted by Tamara Lundgren and Stefano Gaggini, Senior Vice President and CFO, to discuss the results.
The EMERALD trial results revealed that elacestrant significantly improves progression-free survival (PFS) in patients with ER+/HER2- advanced breast cancer. As the first oral selective estrogen receptor degrader (SERD), elacestrant reduced the risk of progression or death by 30% in the overall population and 45% in patients with estrogen receptor mutations (mESR1). The PFS rate at 12 months was 22.32% for elacestrant compared to 9.42% with standard care. Both Menarini and Radius Health are optimistic about the implications of these findings for regulatory submissions in 2022.
BOSTON, Dec. 08, 2021 - Radius Health announced a conference call on December 8, 2021, at 4:00 p.m. ET. The call will discuss topline results from the wearABLe Phase 3 trial and review data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. Interested parties can join via a domestic dial-in number at 1 (866) 323-7965 or internationally at 1 (346) 406-0961, using conference ID 7691981. A replay will be available later on the same day and archived for 90 days on the Company's website.
Radius Health, Inc. (NASDAQ: RDUS) announced the topline results of its phase 3 wearABLe study, comparing the abaloparatide transdermal system (abalo-TDS) with TYMLOS (abaloparatide subcutaneous injection) in postmenopausal women with osteoporosis. The study did not meet its primary endpoint of non-inferiority, showing a lumbar spine BMD increase of 7.1% for abalo-TDS versus 10.9% for TYMLOS. Both treatments were well tolerated, with no significant safety issues found. The data will inform future plans for abalo-TDS development.
BOSTON, Nov. 11, 2021 – Radius Health, Inc. (NASDAQ: RDUS) will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 8:40 a.m. ET, featuring a fireside chat and investor meetings. A live webcast of the chat will be accessible via the Company’s website, with a 90-day replay available post-event. Radius focuses on unmet medical needs in bone health, orphan diseases, and oncology, with its lead product TYMLOS® FDA-approved for postmenopausal osteoporosis. The pipeline includes multiple investigational drugs for various conditions.
Radius Health reported Q3 2021 net revenue of $57 million, a 13% increase from Q3 2020. However, total company revenue dropped by 27% year-over-year due to a lack of license revenue in the current quarter. Adjusted EBITDA was negative $11 million compared to a positive $9 million in the previous year. The company plans to lower its FY 2021 TYMLOS revenue forecast to $210-$220 million and adjusted EBITDA to a loss of $5-$15 million. Notably, the EMERALD study showed positive results for elacestrant, with regulatory submissions planned for 2022.
Radius Health, Inc. (NASDAQ: RDUS) will release its third quarter financial results on November 8, 2021, followed by a conference call at 8:30 a.m. ET. Investors can join via a domestic dial-in at 1 (855) 404-2458 or internationally at 1 (430) 775-1272, using conference ID 9322858. A replay will be available the same day at 11:30 a.m. ET. Radius focuses on unmet medical needs in bone health and oncology, with its lead product, TYMLOS®, approved for high-risk postmenopausal women with osteoporosis.
Radius Health (NASDAQ: RDUS) and Menarini Group announced that their EMERALD study met its primary endpoints, demonstrating significant progression-free survival (PFS) in patients with ER+/HER2- advanced or metastatic breast cancer (mBC). Elacestrant, the first oral selective estrogen receptor degrader (SERD), showed positive results as a monotherapy compared to standard of care. Regulatory submissions are planned in the U.S. and EU for 2022, with data presentation scheduled at the San Antonio Breast Cancer Symposium in December 2021.
Radius Health announced positive topline results from the ATOM study, which evaluated abaloparatide for treating osteoporosis in men. The study met its primary endpoint, showing a significant increase in lumbar spine bone mineral density (BMD) at 12 months (8.5% vs. 1.2% placebo, p-value < 0.0001). Secondary endpoints were also met, reflecting improvements in BMD at 6 months and at the hip and femoral neck after 12 months. The safety profile aligns with previous trials, and a supplemental new drug application (sNDA) is planned for Q1 2022.
Radius Health has updated the TYMLOS® label to clarify its mechanism of action, emphasizing its role in stimulating new bone formation. This change, effective September 20, 2021, aligns with the company's focus on treating postmenopausal women at high risk for fractures. Additionally, the company has welcomed Danielle Holtschlag as the new Head of Sales, bringing over 20 years of experience. Notably, Radius added approximately 3,000 new TYMLOS patients from July to August, reflecting a 13% increase year-over-year.
FAQ
What is the current stock price of Radius Recycling (RDUS)?
What is the market cap of Radius Recycling (RDUS)?
What is Radius Recycling, Inc.?
What does Radius Recycling do?
Where is Radius Recycling headquartered?
What are the key business units of Radius Recycling?
How has Radius Recycling performed financially?
What are the latest financial results for Radius Recycling?
What are Radius Recycling's strategic initiatives?
Who is the CEO of Radius Recycling?
How does Radius Recycling contribute to sustainability?
Where can I find more information about Radius Recycling?
